Search Results - lymphoma

10 Results Sort By:
Retargetable and Metabolically Tunable CAR Cell Platforms for Durable, Antigen‑Specific Cancer Therapy
SHORT DESCRIPTION A modular immunotherapy platform that combines hapten‑redirectable chimeric antigen receptor (CAR) constructs with itaconate‑programmed, memory‑like immune cells to deliver safer, more durable, and tunable antigen‑specific responses across hematologic and solid tumors. NU TECH ID NU 2023-021, NU 2024-077 INVENTORS Ashima...
Published: 6/10/2026   |   Updated: 6/10/2026   |   Inventor(s):  
Keywords(s): Autoimmune disease, Cancer Treatment, Cancer/Oncology, Cell therapy, Immunology, Immunotherapy, Inflammation, Leukemia, Lymphoma, Targeted therapy, Therapeutics
Category(s): Life Sciences > Therapeutics
Use of Nucleotide Synthesis Inhibitors for Targeted Therapy in MLL3/4 COMPASS Mutant Cancer
NU 2022-053 INVENTORS Ali Shilatifard (Feinberg School of Medicine, Department of Biochemistry and Molecular Genetics)* Zibo Zhao (Feinberg School of Medicine, Department of Biochemistry and Molecular Genetics)* SHORT DESCRIPTION A therapeutic platform that targets MLL3/4 COMPASS mutant cancers by using nucleotide synthesis inhibitors to disrupt...
Published: 6/16/2026   |   Updated: 4/29/2026   |   Inventor(s):  
Keywords(s): BIO2026, Bladder cancer, Breast cancer, Cancer/Oncology, Colon cancer, Gastric cancer, Leukemia, Lung cancer, Lymphoma, Prostate cancer, Targeted therapy, Therapeutics
Category(s): Life Sciences > Therapeutics
Covalent PRC2 Inhibitors for Advanced Cancer Therapeutics
SHORT DESCRIPTION Covalent inhibitors and proteolysis-targeting chimera (PROTAC) degraders targeting components of the PRC2 complex (EZH and EED) to block both enzymatic and non-enzymatic functions, offering robust anti-tumor efficacy. INVENTORS Gary Schiltz (Weinberg College of Arts and Sciences, Department of Chemistry)* Jindan...
Published: 6/16/2026   |   Updated: 3/5/2026   |   Inventor(s):  
Keywords(s): AUTM26C1, BIAUTM1, BIO2026, Bladder cancer, Breast cancer, Cancer/Oncology, Covalent inhibitor, Lymphoma, Melanoma, PreSeed/Seed, Prostate cancer, PROTAC, Small molecule, Targeted protein degradation, Targeted therapy, Therapeutics
Category(s): Life Sciences > Therapeutics
Therapy for T-Cell Lymphoma
NU2022-104 INVENTORS Jaehyuk Choi* Jay Daniels Jurgen Ruland Tim Wartweig SHORT DESCRIPTION Targeting PD-1 related mechanisms for treatment of aggressive T-Cell lymphomas BACKGROUND T-cell non-Hodgkin lymphomas (T-NHLs) are highly aggressive cancers that can be resistant to chemotherapies. The molecular pathogenesis of these cancers remains...
Published: 6/16/2026   |   Updated: 5/14/2024   |   Inventor(s):  
Keywords(s): BIO2026, Cancer/Oncology, Lymphoma, Small molecule, Targeted therapy, Therapeutics
Category(s): Life Sciences > Therapeutics
Optimized Monospecific or Bicistronic Chimeric Antigen Receptor (CAR) Constructs Targeting CD19 and CD20
Description of Technology: Patients with chemotherapy-refractory, diffuse large B-cell lymphoma (DLBCL) have poor prognoses. CD19 and CD20 are promising targets for the treatment of B-Cell malignancies. However, despite the initial promising results from anti-CD19 CAR therapy, only 30-35% of patients with DLBCL achieve remissions lasting longer than...
Published: 4/23/2026   |   Updated: 8/2/2023   |   Inventor(s): James Kochenderfer, Norris Lam
Keywords(s): act, adoptive cell therapy, Autoimmune, B Cell Malignancies, BICISTRONIC, CAR, CD19, CD20, chimeric antigen receptor, Kochenderfer, Leukemia, lymphoma, Monospecific
Category(s): Application > Therapeutics, Collaboration Sought > Licensing, Collaboration Sought > Collaboration, TherapeuticArea > Immunology, TherapeuticArea > Oncology
Bicistronic Chimeric Antigen Receptor (CAR) Constructs Targeting CD19 and CD20
Abstract: CD19 and CD20 are promising targets for the treatment of B-Cell malignancies.  Unfortunately, some clinical studies have shown that there is a loss of CD19 or CD20 expression in various cases of lymphomas and leukemias, particularly after treatment with an agent that targets CD19 (e.g., anti-CD19 CAR-T). However, studies have shown that expression...
Published: 5/14/2025   |   Updated: 8/2/2023   |   Inventor(s): James Kochenderfer, Shicheng Yang
Keywords(s): act, adoptive cell therapy, B Cell Malignancies, BICISTRONIC, CAR, CD19, CD20, chimeric antigen receptor, Kochenderfer, Leukemia, lymphoma
Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Oncology, Application > Therapeutics
A Target for the Development of Diagnostics and Therapeutics for Abnormal Hematopoiesis
The zinc finger protein ZFP36L2 has been shown by the inventors to play an essential role in hematopoiesis, a process that is dysregulated in hematological cancers, anemia, and other conditions. Thus, ZFP36L2 has promise for use in a diagnostic test to detect abnormal hematopoiesis, or as a target for the development of therapeutics to treat abnormal...
Published: 5/15/2025   |   Updated: 12/6/2022   |   Inventor(s): Deborah Stumpo, Perry Blackshear
Keywords(s): (4)r syndrome, anemia, Blood, C syndrome, CANCER, Chromosome 4 ring syndrome, Chromosome 6 ring syndrome, Chromosome 7 ring syndrome, Chronic myelogenous leukemia, diagnostic, Diagnostic assay, diagnostic test, G syndrome, Hematologic, Hematopoiesis, Hypertelorism with esophageal abnormality and hypospadias, IAXXXX, IBXXXX, IXXXXX, Leukemia, lymphoma, N syndrome, Patent Category - Biotechnology, R(6) syndrome, R(7) syndrome, Syndrome X, therapeutic, Thrombocytopenia 2, Thrombocytopenia chromosome breakage, Tristetraprolin, W syndrome, W syndrome; Syndrome W, ZFP36L2, zinc finger
Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Diagnostics, Application > Research Materials, Application > Therapeutics
Eeyarestatins: Novel Deubiquitination Inhibitors for the Treatment of Drug-Resistant Cancers
The ubiquitin-proteasome system has recently been recognized to play a central role in tumor biology. Bortezomib, an inhibitor of the chymotrypsin-like activity of the proteasome, has clinical activity in a variety of hematologic malignancies and is FDA approved for use in Multiple Myeloma and Mantle Cell Lymphoma. The present invention for the first...
Published: 10/28/2024   |   Updated: 12/6/2022   |   Inventor(s): Helena Mora-Jensen, Qiuyan Wang, Yihong Ye, Adrian Wiestner
Keywords(s): Active, Against, BBXXXX, Bortezomib, CANCER, CB5EXX, CB5XXX, CBXXXX, Cells, Chronic lymphocytic leukemia, COMPOSITION, CXXXXX, DB4AXX, DB4XXX, DBXXXX, Deubiquination, DXXXXX, Eeyarestatin, Hematologic, Highly, HIV AIDS - Therapeutics, Including, inhibitor, lymphoma, Mantle cell lymphoma, MULTIPLE MYELOMA, Proteasome, RESISTANT, That, tumor
Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Infectious Disease, Application > Therapeutics, TherapeuticArea > Oncology
Methods for Expression and Purification of Immunotoxins
The invention concerns immunotoxins and methods of making the immunotoxins. Targeting of the immunotoxins occurs via an antibody that is specific to T cells. This allows the specific ablation of malignant T cells and resting T cells. The transient ablation of resting T cells can "reset" the immune system by accentuating tolerizing responses. As...
Published: 10/28/2024   |   Updated: 12/6/2022   |   Inventor(s): David Neville
Keywords(s): Aplastic anemia, Are, Bivalent, CB6XXX, CBXXXX, COMPLEX, CXXXXX, ESSENTIAL, Graft versus host disease, IB3XXX, IBXXXX, Immunotoxin, IXXXXX, LOW, lymphoma, Media, PASTORIS, PICHIA, production, temperature
Category(s): Collaboration Sought > Licensing, Application > Research Materials, TherapeuticArea > Immunology, Application > Diagnostics, Application > Therapeutics, TherapeuticArea > Oncology
Immunotoxin with in-vivo T cell Suppressant Activity
The invention concerns immunotoxins and methods of using the immunotoxins for the treatment of autoimmune diseases and T cell malignancies. The immunotoxins are targeted via an antibody that is specific to T cells. This allows the specific ablation of malignant T cells and resting T cells. The transient ablation of resting T cells can "reset" the...
Published: 10/28/2024   |   Updated: 12/6/2022   |   Inventor(s): David Neville
Keywords(s): Activity, Aplastic anemia, CB1XXX, CBXXXX, Cell, CXXXXX, IB3XXX, IBXXXX, IMMUNE, Immunotoxin, IMMUNOTOXINS, INDUCING, IN-VIVO, IXXXXX, lymphoma, Methods, Novel, SUPPRESSANT, T, TOLERANCE, UAXXXX, Vivo
Category(s): Collaboration Sought > Licensing, TherapeuticArea > Oncology, TherapeuticArea > Immunology, Application > Diagnostics, Application > Research Materials, Application > Therapeutics, TherapeuticArea > Rare/Neglected Diseases